$VKTX — BUY 📊

$VKTX — BUY 📊 Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. 🎯 Q2 2026 | EPS $-1.37 vs $-0.91 🔴 💡 Consensus views the higher spending as a negative, expecting continued cash burn and dilution risk. Our variant view is that the spending accelerates trial timelines and increases the probability of a successful readout, which is not fully priced in after the sell-off. 📉 Reward/Risk: 3.6:1 🏢 Business Quality: 7/10 📊 Valuation: fair 🔮 Catalyst: Phase 3 topline data for lead candidate (e.g., VK001 for NASH) 💰 Entry: $30.38, stop $25, target $50 ⚖️ Buy VKTX ahead of pivotal Phase 3 data; recent sell-off on EPS miss overlooked accelerated R&D progress, setting up a 3.6:1 risk/reward with upcoming binary catalyst. 📊 Our read: BUY. Full analysis → https://stockduty.xyz/s/VKTX0622

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.